Brain zaps may tame sensory overload in kids with autism

NCT ID NCT07182331

ENROLLING_BY_INVITATION Symptom relief Sponsor: Neurolab Plus Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a non-invasive brain stimulation technique called cTBS can improve how children with autism (ages 6-12) combine what they see and hear. Forty children will receive either real or sham stimulation over 10 sessions. Researchers will use brain scans, genetic tests, and sensory tasks to see if the treatment works and who benefits most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: continuous theta-burst stimulation (cTBS) - a type of non-invasive brain stimulation
What this could lead to: If it works, this could point toward a non-drug treatment to help children with autism process sights and sounds more easily, potentially reducing sensory overload.
What could go wrong: This is a small, early-stage study with only 40 children. The treatment may not work better than sham stimulation, and results may not apply to all children with autism. Brain stimulation can sometimes cause discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER (ASD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder neurodevelopmental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER (ASD

Contacts and locations

Locations

Neurolab Plus

Almaty, 050000, Kazakhstan
Non-profit joint-stock company "Al-Farabi Kazakh National University"

Almaty, 050040, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.